CN101877963A - 延缓临床确诊的多发性硬化症发作的方法 - Google Patents
延缓临床确诊的多发性硬化症发作的方法 Download PDFInfo
- Publication number
- CN101877963A CN101877963A CN2008801187747A CN200880118774A CN101877963A CN 101877963 A CN101877963 A CN 101877963A CN 2008801187747 A CN2008801187747 A CN 2008801187747A CN 200880118774 A CN200880118774 A CN 200880118774A CN 101877963 A CN101877963 A CN 101877963A
- Authority
- CN
- China
- Prior art keywords
- patient
- treatment
- multiple sclerosis
- glatiramer acetate
- pathology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
GA 20mg比 安慰剂数据分析集 | 危险比 | 危险比的95%置信下限 | 危险比的95%置信上限 | Pr>Chisq |
ITT(481名患者) | 0.555 | 0.396 | 0.770 | 0.0005 |
完成者(423名患者) | 0.581 | 0.424 | 0.815 | 0.0017 |
ITT+有效的随访(481名患者) | 0.556 | 0.399 | 0.774 | 0.0005 |
Claims (53)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US471007P | 2007-11-28 | 2007-11-28 | |
US61/004,710 | 2007-11-28 | ||
US527107P | 2007-12-03 | 2007-12-03 | |
US61/005,271 | 2007-12-03 | ||
US714107P | 2007-12-11 | 2007-12-11 | |
US61/007,141 | 2007-12-11 | ||
US19245508P | 2008-09-17 | 2008-09-17 | |
US61/192,455 | 2008-09-17 | ||
PCT/US2008/013146 WO2009070298A1 (en) | 2007-11-28 | 2008-11-26 | Method of delaying the onset of clinically definite multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101877963A true CN101877963A (zh) | 2010-11-03 |
Family
ID=40678899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801187747A Pending CN101877963A (zh) | 2007-11-28 | 2008-11-26 | 延缓临床确诊的多发性硬化症发作的方法 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20090149541A1 (zh) |
EP (1) | EP2111105A4 (zh) |
JP (1) | JP2011504925A (zh) |
KR (1) | KR20100102620A (zh) |
CN (1) | CN101877963A (zh) |
AU (1) | AU2008330093A1 (zh) |
BR (1) | BRPI0819001A2 (zh) |
CA (1) | CA2702437C (zh) |
EA (1) | EA201070656A1 (zh) |
IL (1) | IL205856A0 (zh) |
MX (1) | MX2010005676A (zh) |
WO (1) | WO2009070298A1 (zh) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
AU2003222427B8 (en) * | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
EP2277887A3 (en) | 2001-10-19 | 2011-02-16 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
US7807847B2 (en) | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
EP1838326A4 (en) * | 2005-02-02 | 2009-09-30 | Teva Pharma | PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS |
PT1848415E (pt) * | 2005-02-17 | 2013-06-27 | Teva Pharma | Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla |
US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
US9006217B2 (en) | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
AU2009312355C1 (en) * | 2008-11-06 | 2016-02-18 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
AU2009202685B1 (en) | 2009-06-30 | 2010-08-19 | Ino Therapeutics Llc | Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension |
US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
CA2697570C (en) * | 2009-07-15 | 2011-11-01 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
RS52885B (en) | 2009-08-20 | 2014-02-28 | Yeda Research And Development Co. Ltd. | LOW-FREQUENCY GLATIRAMER ACETATOM THERAPY |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
JP2013516457A (ja) * | 2010-01-05 | 2013-05-13 | バスキュラー バイオジェニックス リミテッド | Vb−201を用いた併用治療法 |
US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
AU2012225268B2 (en) | 2011-03-10 | 2016-10-20 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
TW201326399A (zh) | 2011-10-10 | 2013-07-01 | Teva Pharma | 用於預測對格拉替雷(glatiramer)醋酸鹽之臨床反應之單核苷酸多型性之判定 |
ES2574761T3 (es) | 2011-10-31 | 2016-06-21 | Xeris Pharmaceuticals, Inc. | Formulaciones para el tratamiento de la diabetes |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
MX2015004563A (es) | 2012-10-10 | 2015-07-14 | Teva Pharma | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
AU2015300944B2 (en) | 2014-08-06 | 2019-07-11 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
WO2016084023A1 (en) | 2014-11-26 | 2016-06-02 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
EP3600553A4 (en) | 2017-03-26 | 2020-09-02 | Mapi Pharma Ltd. | GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS |
AU2018275686B2 (en) | 2017-06-02 | 2024-02-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800808A (en) * | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
EP1098902A4 (en) * | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES |
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6514938B1 (en) * | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6844314B2 (en) * | 2000-01-20 | 2005-01-18 | Yeda Research Development Co., Ltd. | Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
US7022663B2 (en) * | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
US6936599B2 (en) * | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
MXPA04005433A (es) * | 2001-12-04 | 2004-10-11 | Teva Pharma | Proceso para la medicion de la potencia de acetato de glatiramero. |
US20040048871A1 (en) * | 2002-09-09 | 2004-03-11 | Rowe Vernon D. | Use of high dose intravenous methotrexate, with leucovorin rescue, to treat early multiple sclerosis and other diseases of the central nervous system |
CA2541445A1 (en) * | 2003-10-31 | 2005-05-12 | Teva Pharmaceutical Industries Ltd. | Nanoparticles for drug delivery |
US20050220764A1 (en) * | 2004-04-01 | 2005-10-06 | Schering Aktiengesellschaft | Higher-doses of interferon-beta for treatment of multiple sclerosis |
WO2005108610A2 (en) * | 2004-04-05 | 2005-11-17 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for the selection of subjects for multiple sclerosis therapy |
ATE536363T1 (de) * | 2004-09-09 | 2011-12-15 | Teva Pharma | Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure |
WO2006029411A2 (en) * | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
EP1838326A4 (en) * | 2005-02-02 | 2009-09-30 | Teva Pharma | PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS |
US20060240463A1 (en) * | 2005-04-25 | 2006-10-26 | Rappaport Family Institute For Research In The Medical Sciences | Markers associated with the therapeutic efficacy of glatiramer acetate |
US20070161566A1 (en) * | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
-
2008
- 2008-11-26 AU AU2008330093A patent/AU2008330093A1/en not_active Abandoned
- 2008-11-26 CN CN2008801187747A patent/CN101877963A/zh active Pending
- 2008-11-26 EA EA201070656A patent/EA201070656A1/ru unknown
- 2008-11-26 WO PCT/US2008/013146 patent/WO2009070298A1/en active Application Filing
- 2008-11-26 US US12/315,009 patent/US20090149541A1/en not_active Abandoned
- 2008-11-26 KR KR1020107014015A patent/KR20100102620A/ko not_active Application Discontinuation
- 2008-11-26 JP JP2010536004A patent/JP2011504925A/ja not_active Withdrawn
- 2008-11-26 MX MX2010005676A patent/MX2010005676A/es not_active Application Discontinuation
- 2008-11-26 CA CA2702437A patent/CA2702437C/en active Active
- 2008-11-26 EP EP08853455A patent/EP2111105A4/en not_active Withdrawn
- 2008-11-26 BR BRPI0819001-1A2A patent/BRPI0819001A2/pt not_active Application Discontinuation
-
2010
- 2010-05-20 IL IL205856A patent/IL205856A0/en unknown
- 2010-08-23 US US12/861,655 patent/US20100305023A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
张霞等: "神经系统常见疾病治疗现状", 《华西医学》 * |
田林郁等: "尿酸在中枢神经系统脱髓鞘疾病诊断、治疗和预防中的意义(综述)", 《中国神经免疫学和神经病学杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
EA201070656A1 (ru) | 2010-12-30 |
US20090149541A1 (en) | 2009-06-11 |
EP2111105A1 (en) | 2009-10-28 |
BRPI0819001A2 (pt) | 2014-10-07 |
KR20100102620A (ko) | 2010-09-24 |
EP2111105A4 (en) | 2011-05-04 |
MX2010005676A (es) | 2010-08-06 |
CA2702437C (en) | 2013-06-25 |
WO2009070298A9 (en) | 2010-07-01 |
IL205856A0 (en) | 2010-11-30 |
JP2011504925A (ja) | 2011-02-17 |
AU2008330093A1 (en) | 2009-06-04 |
CA2702437A1 (en) | 2009-06-04 |
US20100305023A1 (en) | 2010-12-02 |
WO2009070298A1 (en) | 2009-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101877963A (zh) | 延缓临床确诊的多发性硬化症发作的方法 | |
Rosenfeld et al. | Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial | |
Jaffe et al. | A phase 1 study of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration | |
Lange et al. | Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain | |
Chen et al. | Brain lesion size and location: effects on motor recovery and functional outcome in stroke patients | |
Mackensen et al. | Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndrome | |
Benson et al. | Optical coherence tomography analysis of the macula after scleral buckle surgery for retinal detachment | |
Kim et al. | Prevalence of primary open-angle glaucoma in central South Korea: the Namil study | |
Krishnan et al. | Oxaliplatin‐induced neurotoxicity and the development of neuropathy | |
Bhola et al. | Recurrence of amblyopia after occlusion therapy | |
Evans et al. | Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community | |
Wallace et al. | A randomized trial of increasing patching for amblyopia | |
Balcer et al. | Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS | |
Van Eijs et al. | Brush-evoked allodynia predicts outcome of spinal cord stimulation in complex regional pain syndrome type 1 | |
CN104284663A (zh) | 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途 | |
Hunter et al. | Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: an analysis from the EPOC (Evaluate Patient OutComes) trial | |
Pratt | Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia | |
Invernizzi et al. | Early and Late Retinal Pigment Epithelium Tears after Anti–Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration | |
Tong et al. | Altered expression level of inflammation-related genes and long-term changes in ocular surface after trabeculectomy, a prospective cohort study | |
Raine et al. | A 26‐week feasibility study comparing the efficacy and safety of modified‐release prednisone with immediate‐release prednisolone in newly diagnosed cases of giant cell arteritis | |
Nixon et al. | Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab | |
Cleary et al. | Does Computed Tomography–Based Muscle Density Predict Muscle Function and Health‐Related Quality of Life in Patients With Idiopathic Inflammatory Myopathies? | |
Watson et al. | Cognitive trajectories following onset of psychosis: a meta-analysis | |
Graham Jr et al. | Clinical and behavioral characteristics in FG syndrome | |
Hess et al. | Tamoxifen retinopathy and macular telangiectasia type 2: similarities and differences on multimodal retinal imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. Free format text: FORMER OWNER: TEVA PHARMA Effective date: 20110330 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: PEITADIKAWA, ISRAEL TO: ROHAWATT, ISRAEL |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110330 Address after: Israel Lodha Watt Applicant after: Yeda research and Development Co Ltd Address before: Israel Peta Dick Wa Applicant before: Teva Pharmaceutical Industries Ltd. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1147036 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20101103 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1147036 Country of ref document: HK |